Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO adverse drug reaction database VigiBase.
Our study aimed to identify and characterize thyroid dysfunctions associated with immume checkpoint inhibitors (ICIs). Data were obtained from VigiBase, between January 1, 2011 to March 6, 2019. All thyroid drug-adverse events are classified by group queries according to the Medical Dictionary for Regulatory Activities. Information component (IC) and reporting odds ratio (ROR) were considered as measures of disproportionality for the assessment of association between ICIs and thyroid dysfunctions. We used IC to identify meaningful drug-adverse events while using ROR to compare differences in the reporting of drug-adverse events caused by different ICI subgroups. Positive IC values are deemed significant. Compared with the full database, the following ICI-associated thyroid dysfunctions were over-reported: hypothyroidism (1125 reports for ICIs vs 12495 for all drugs; Information Component 4.28 [95% CI 4.18-4.35]), hyperthyroidism (926 vs 7538; 4.66 [95% CI 4.55-4.74]), thyroiditis (294 vs 1237; 5.40 [95% CI 5.21-5.54]), thyrotoxic crisis (11 vs 288; 3.55 [95% CI 2.61-4.20]). Hypothyroidism was over-reported for patients treated with ICI combination therapy versus those treated with ICI monotherapy (ROR 1.3 [95% CI 1.1-1.7]), and the same was observed for hyperthyroidism (ROR 1.9 [95% CI 1.5-2.4]), thyroiditis (ROR 3.3 [95% CI 2.3-4.8]), thyrotoxic crisis (ROR 11.5 [95% CI 2.4-53.8]). All 11 thyrotoxic crisis cases were malignant melanoma patients, of which 7 occurred under ICI combination therapy. Thyroid dysfunction may occur after ICI therapies, and severe thyrotoxic crisis may even occurs. Raising awareness of ICI-associated thyroid dysfunction can improve the detection and treatment of these diseases.